Pub Date : 2025-12-01Epub Date: 2025-12-11DOI: 10.1080/08037051.2025.2594268
Babu Karavadra, Alexander D Elia, Alena Shantsila, Gregory Y H Lip, Eduard Shantsila
Background: Hypertension is the UK's most common treatable cause of mortality and morbidity, including cardiovascular disease (CVD), renal disease and dementia.
Objective: This systematic review has explored the efficacy and safety of commencing full-dose antihypertensive treatment in individuals with essential hypertension.
Method: Method16 randomised controlled trials (RCTs) were eligible for inclusion, with some RCTs assessing more than one treatment. The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. Eligible studies included 12 RCTs that compared full vs low doses and 19 RCTs that compared full starting doses vs placebo. The primary outcome was the difference in blood pressure reduction compared to controls (reported or calculated). ResultsUsing full doses compared to low doses led to better BP reduction (overall, 3.9/2.2 mmHg lower achieved BP) without an increase in adverse effects. This notion is supported by the changes achieved with full-dose treatment initiation compared to placebo (average over all studies: 11.4 [4.4]/6.5 [2.9] mmHg).
Conclusions: This review indicates that initiating full-dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited, and further RCTs are required to assess this in specific patient groups to assess safety and efficac.
{"title":"A systematic review of commencing full-dose antihypertensives in newly diagnosed hypertension.","authors":"Babu Karavadra, Alexander D Elia, Alena Shantsila, Gregory Y H Lip, Eduard Shantsila","doi":"10.1080/08037051.2025.2594268","DOIUrl":"10.1080/08037051.2025.2594268","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is the UK's most common treatable cause of mortality and morbidity, including cardiovascular disease (CVD), renal disease and dementia.</p><p><strong>Objective: </strong>This systematic review has explored the efficacy and safety of commencing full-dose antihypertensive treatment in individuals with essential hypertension.</p><p><strong>Method: </strong>Method16 randomised controlled trials (RCTs) were eligible for inclusion, with some RCTs assessing more than one treatment. The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. Eligible studies included 12 RCTs that compared full vs low doses and 19 RCTs that compared full starting doses vs placebo. The primary outcome was the difference in blood pressure reduction compared to controls (reported or calculated). ResultsUsing full doses compared to low doses led to better BP reduction (overall, 3.9/2.2 mmHg lower achieved BP) without an increase in adverse effects. This notion is supported by the changes achieved with full-dose treatment initiation compared to placebo (average over all studies: 11.4 [4.4]/6.5 [2.9] mmHg).</p><p><strong>Conclusions: </strong>This review indicates that initiating full-dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited, and further RCTs are required to assess this in specific patient groups to assess safety and efficac.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2594268"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.1080/08037051.2025.2469260
Elmukhtar Habas, Amnna Rayani, Aml Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Ala Habas, Elmehdi Errayes, Gamal Alfitori
BackgroundIntradialytic hypotension (IDH) is the most prevalent complication during hemodialysis (HD) sessions, affecting 10% to 12% of patients. It is linked with temporary ischemic stress in vital organs, increasing patient mortality. Various definitions of IDH have been proposed, and a strong correlation has been found between patient outcomes and the absolute lowest systolic blood pressure. The most probable underlying pathophysiology of IDH involves a reduced effective blood volume and decreased plasma tonicity. Optimizing the dialysis prescription and interventions during and after the dialysis session is sometimes effective for reducing IDH risk.Aim and MethodThis review discusses the pathophysiology, prevention, and therapy of IDH updates. To achieve this aim, Scopus, EMBASE, PubMed, Google, and Google Scholar were searched for articles published in the last two decades using phrases and keywords.ConclusionIntradialytic pathophysiology is ambiguous and unclear. The evidence for the effectiveness of the known therapies and maneuvers is limited. Ideally, IDH prevention should be the target; however, IDH management is sometimes needed. Different obstacles require further clinical research.
{"title":"Intradialytic Hypotension Pathophysiology and Therapy Update: Review and Update.","authors":"Elmukhtar Habas, Amnna Rayani, Aml Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Ala Habas, Elmehdi Errayes, Gamal Alfitori","doi":"10.1080/08037051.2025.2469260","DOIUrl":"https://doi.org/10.1080/08037051.2025.2469260","url":null,"abstract":"<p><p>BackgroundIntradialytic hypotension (IDH) is the most prevalent complication during hemodialysis (HD) sessions, affecting 10% to 12% of patients. It is linked with temporary ischemic stress in vital organs, increasing patient mortality. Various definitions of IDH have been proposed, and a strong correlation has been found between patient outcomes and the absolute lowest systolic blood pressure. The most probable underlying pathophysiology of IDH involves a reduced effective blood volume and decreased plasma tonicity. Optimizing the dialysis prescription and interventions during and after the dialysis session is sometimes effective for reducing IDH risk.Aim and MethodThis review discusses the pathophysiology, prevention, and therapy of IDH updates. To achieve this aim, Scopus, EMBASE, PubMed, Google, and Google Scholar were searched for articles published in the last two decades using phrases and keywords.ConclusionIntradialytic pathophysiology is ambiguous and unclear. The evidence for the effectiveness of the known therapies and maneuvers is limited. Ideally, IDH prevention should be the target; however, IDH management is sometimes needed. Different obstacles require further clinical research.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"1-18"},"PeriodicalIF":1.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-09-23DOI: 10.1080/08037051.2024.2405156
Bo He, Dapeng Ji, Bo Zhang
Objective: This study investigates the relationship between hypertension, dysregulation of the autonomic nervous system, heart rate variability (HRV), and chronic inflammation.
Methods: We analysed a cohort of 50 hypertensive patients treated at the affiliated Hospital of Jianghan University. The average systolic and diastolic blood pressures (BPs) in this group were 155.26 and 95.32 mmHg, respectively. A control group of 50 healthy volunteers, undergoing routine physical examinations at the same hospital, was also analysed.
Results: The average systolic BP of the control group was 115.64 ± 10.27 mmHg, and the average diastolic BP was 75.33 ± 8.25 mmHg. In contrast, the experimental group exhibited an average systolic BP of 155.26 ± 20.13 mmHg and an average diastolic BP of 95.32 ± 12.16 mmHg. Both systolic and diastolic BPs were significantly higher in the hypertensive group (p < 0.05). The experimental group also demonstrated reduced HRV and skin conductance response, alongside increased BP variability (BPV), urinary epinephrine levels and prolonged pupillary light reaction time compared to controls (p < 0.05). Notably, Standard Deviation of Normal to Normal Intervals (SDNN) and Root Mean Square of Successive Differences (RMSSD) values were significantly lower in the experimental group (p < 0.05). Furthermore, levels of inflammatory markers such as CRP, TNF-α, IL-6 and IL-1β were markedly elevated in hypertensive patients (p < 0.05). Negative correlations were observed between systolic and diastolic BP with HRV metrics, while positive correlations were found between BP and BPV as well as urinary adrenaline levels.
Conclusions: The findings indicate that hypertension is closely associated with autonomic nervous system dysfunction, reduced HRV and increased chronic inflammation. A comprehensive approach to hypertension management should integrate these interrelated physiological and pathological mechanisms, with potential therapeutic interventions targeting autonomic function and inflammatory states.
目的:本研究探讨了高血压、自律神经系统失调、心率变异性和慢性炎症之间的关系:本研究探讨了高血压、自主神经系统失调、心率变异性(HRV)和慢性炎症之间的关系:我们分析了在江汉大学附属医院接受治疗的 50 名高血压患者。该组患者的平均收缩压和舒张压分别为 155.26 毫米汞柱和 95.32 毫米汞柱。同时还分析了在同一家医院接受常规体检的 50 名健康志愿者组成的对照组:结果:对照组的平均收缩压为 115.64 ± 10.27 mmHg,平均舒张压为 75.33 ± 8.25 mmHg。相比之下,实验组的平均收缩压为(155.26 ± 20.13)毫米汞柱,平均舒张压为(95.32 ± 12.16)毫米汞柱。高血压组的收缩压和舒张压均明显高于实验组(P P P P 结论):研究结果表明,高血压与自律神经系统功能障碍、心率变异性降低和慢性炎症增加密切相关。治疗高血压的综合方法应整合这些相互关联的生理和病理机制,并针对自律神经功能和炎症状态采取潜在的治疗干预措施。
{"title":"Hypertension and its correlation with autonomic nervous system dysfunction, heart rate variability and chronic inflammation.","authors":"Bo He, Dapeng Ji, Bo Zhang","doi":"10.1080/08037051.2024.2405156","DOIUrl":"https://doi.org/10.1080/08037051.2024.2405156","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the relationship between hypertension, dysregulation of the autonomic nervous system, heart rate variability (HRV), and chronic inflammation.</p><p><strong>Methods: </strong>We analysed a cohort of 50 hypertensive patients treated at the affiliated Hospital of Jianghan University. The average systolic and diastolic blood pressures (BPs) in this group were 155.26 and 95.32 mmHg, respectively. A control group of 50 healthy volunteers, undergoing routine physical examinations at the same hospital, was also analysed.</p><p><strong>Results: </strong>The average systolic BP of the control group was 115.64 ± 10.27 mmHg, and the average diastolic BP was 75.33 ± 8.25 mmHg. In contrast, the experimental group exhibited an average systolic BP of 155.26 ± 20.13 mmHg and an average diastolic BP of 95.32 ± 12.16 mmHg. Both systolic and diastolic BPs were significantly higher in the hypertensive group (<i>p</i> < 0.05). The experimental group also demonstrated reduced HRV and skin conductance response, alongside increased BP variability (BPV), urinary epinephrine levels and prolonged pupillary light reaction time compared to controls (<i>p</i> < 0.05). Notably, Standard Deviation of Normal to Normal Intervals (SDNN) and Root Mean Square of Successive Differences (RMSSD) values were significantly lower in the experimental group (<i>p</i> < 0.05). Furthermore, levels of inflammatory markers such as CRP, TNF-α, IL-6 and IL-1β were markedly elevated in hypertensive patients (<i>p</i> < 0.05). Negative correlations were observed between systolic and diastolic BP with HRV metrics, while positive correlations were found between BP and BPV as well as urinary adrenaline levels.</p><p><strong>Conclusions: </strong>The findings indicate that hypertension is closely associated with autonomic nervous system dysfunction, reduced HRV and increased chronic inflammation. A comprehensive approach to hypertension management should integrate these interrelated physiological and pathological mechanisms, with potential therapeutic interventions targeting autonomic function and inflammatory states.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2405156"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-10-23DOI: 10.1080/08037051.2024.2417887
D Gordin, R Simonsen, I Tikkanen
{"title":"A sham-controlled randomised pilot trial on baroreflex activation therapy in patients with resistant hypertension: What will the future hold?","authors":"D Gordin, R Simonsen, I Tikkanen","doi":"10.1080/08037051.2024.2417887","DOIUrl":"10.1080/08037051.2024.2417887","url":null,"abstract":"","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2417887"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142494646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-03-11DOI: 10.1080/08037051.2024.2323987
Erika Kähönen, Emilia Kähönen, Kristiina Pälve, Janne Hulkkonen, Mika Kähönen, Olli T Raitakari, Nina Hutri, Terho Lehtimäki, Heikki Aatola
Purpose: Socioeconomic status has been related to resting blood pressure (BP) levels at different stages of life. However, the association of childhood socioeconomic status (SES) and adulthood exercise BP is largely unknown. Therefore, we studied the association of childhood SES with adulthood maximal exercise BP.
Materials and methods: This investigation consisted of 373 individuals (53% women) participating in the Cardiovascular Risk in Young Finns Study who had data concerning family SES in childhood (baseline in 1980, at age of 6-18 years) and exercise BP response data in adulthood (follow-up in adulthood in 27-29 years since baseline). A maximal cardiopulmonary exercise test with BP measurements was performed by participants, and peak exercise BP was measured.
Results: In stepwise multivariable analysis including childhood risk factors and lifestyle factors (body mass index, systolic BP, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, insulin, fruit consumption, vegetable consumption, and physical activity), lower family SES in childhood was associated with higher maximal exercise BP in adulthood (β value ± SE, 1.63 ± 0.77, p = 0.035). The association remained significant after further adjustment with participants SES in adulthood (β value ± SE, 1.68 ± 0.65, p = 0.011) and after further adjustment with adulthood body-mass index, systolic BP, maximal exercise capacity, and peak heart rate in exercise (β value ± SE, 1.25 ± 0.56, p = 0.027).
Conclusions: These findings suggest that lower childhood family SES is associated with higher maximal exercise BP in adulthood.
{"title":"Association of childhood socioeconomic status with adulthood maximal exercise blood pressure: the Cardiovascular Risk in Young Finns Study.","authors":"Erika Kähönen, Emilia Kähönen, Kristiina Pälve, Janne Hulkkonen, Mika Kähönen, Olli T Raitakari, Nina Hutri, Terho Lehtimäki, Heikki Aatola","doi":"10.1080/08037051.2024.2323987","DOIUrl":"10.1080/08037051.2024.2323987","url":null,"abstract":"<p><strong>Purpose: </strong>Socioeconomic status has been related to resting blood pressure (BP) levels at different stages of life. However, the association of childhood socioeconomic status (SES) and adulthood exercise BP is largely unknown. Therefore, we studied the association of childhood SES with adulthood maximal exercise BP.</p><p><strong>Materials and methods: </strong>This investigation consisted of 373 individuals (53% women) participating in the Cardiovascular Risk in Young Finns Study who had data concerning family SES in childhood (baseline in 1980, at age of 6-18 years) and exercise BP response data in adulthood (follow-up in adulthood in 27-29 years since baseline). A maximal cardiopulmonary exercise test with BP measurements was performed by participants, and peak exercise BP was measured.</p><p><strong>Results: </strong>In stepwise multivariable analysis including childhood risk factors and lifestyle factors (body mass index, systolic BP, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, insulin, fruit consumption, vegetable consumption, and physical activity), lower family SES in childhood was associated with higher maximal exercise BP in adulthood (β value ± SE, 1.63 ± 0.77, <i>p</i> = 0.035). The association remained significant after further adjustment with participants SES in adulthood (β value ± SE, 1.68 ± 0.65, <i>p</i> = 0.011) and after further adjustment with adulthood body-mass index, systolic BP, maximal exercise capacity, and peak heart rate in exercise (β value ± SE, 1.25 ± 0.56, <i>p</i> = 0.027).</p><p><strong>Conclusions: </strong>These findings suggest that lower childhood family SES is associated with higher maximal exercise BP in adulthood.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2323987"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-07DOI: 10.1080/08037051.2024.2353836
Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys
Objectives: Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. Methods: Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. Results: Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 vs. -0.65 mL/min/1.73 m2 per year; difference in slope, 0.83 mL/min/1.73 m2 per year; 95% confidence interval [CI]: 0.25-1.41, p = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. Conclusions: Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.
目的:有证据表明,与非耐药性动脉高血压(NAH)患者相比,明显耐药性高血压(ATRH)患者的肾功能会日益恶化。我们旨在评估这些患者群体之间肾功能的长期衰退情况,并确定导致肾功能障碍恶化的特定风险因素。研究方法我们对一家高血压卓越中心的 265 名 ATRH 和 NAH 患者的数据进行了回顾性评估。评估了人口统计学特征、合并疾病、实验室检查结果、继发性高血压病因、药物治疗和造影剂暴露情况。针对组间差异,采用线性混合效应模型进行调整。研究结果对前 4 年的随访数据进行了评估。年龄和糖尿病被确定为研究队列中肾功能不全恶化的独立风险因素,在对年龄和糖尿病进行调整后,ATRH 患者的估计肾小球滤过率每年平均下降的幅度比 NAH 患者更大(-1.49 对 -0.65 mL/min/1.73 m2/年;斜率差异为 0.83 mL/min/1.73 m2/年;95% 置信区间 [CI]:0.25-1.41,P<0.05):0.25-1.41, p = 0.005).在未进行 Holm-Bonferroni 校正的亚组分析中,处方 MRA 表明 ATRH 患者的肾功能下降更快。经过校正后,没有任何特定的治疗风险因素与肾功能障碍的加速进展相关。结论与 NAH 相比,ATRH 的肾功能下降速度是 NAH 的两倍,与年龄和糖尿病无关。需要进行更大规模的研究,以揭示高血压患者肾功能障碍的风险因素。
{"title":"Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension.","authors":"Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys","doi":"10.1080/08037051.2024.2353836","DOIUrl":"https://doi.org/10.1080/08037051.2024.2353836","url":null,"abstract":"<p><p><b>Objectives:</b> Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. <b>Methods:</b> Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. <b>Results:</b> Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 <i>vs.</i> -0.65 mL/min/1.73 m<sup>2</sup> per year; difference in slope, 0.83 mL/min/1.73 m<sup>2</sup> per year; 95% confidence interval [CI]: 0.25-1.41, <i>p</i> = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. <b>Conclusions:</b> Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2353836"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-05-31DOI: 10.1080/08037051.2024.2359932
Anette Caroline Kõre, Tuuli Joonsalu, Martin Serg, Priit Pauklin, Jüri Voitk, Indrek Roose, Jaan Eha, Priit Kampus
Background: Carotid-femoral pulse wave velocity (cfPWV) and central pulse pressure (PP) are recognised as significant indicators of vascular health and predictors of cardiovascular outcomes. In this study, associations between central hemodynamics and left ventricular (LV) echocardiographic parameters were investigated in subjects with heart failure with reduced ejection fraction (HFrEF), comparing the results to healthy individuals.
Methods and results: This cross-sectional prospective controlled study included 50 subjects with HFrEF [mean LV ejection fraction (EF) 26 ± 6.5%] and 30 healthy controls (mean LVEF 65.9 ± 5.3%). Pulse wave analysis (PWA) and carotid-femoral pulse wave velocity (cfPWV) were used to measure central hemodynamics and arterial stiffness. The HFrEF group displayed higher cfPWV (8.2 vs. 7.2 m/s, p = 0.007) and lower central (111.3 vs. 121.7 mmHg, p = 0.001) and peripheral (120.1 vs. 131.5 mmHg, p = 0.002) systolic blood pressure. Central pulse pressure (PP) was comparable between the two groups (37.6 vs. 40.4 mmHg, p = 0.169). In the HFrEF group, cfPWV significantly correlated with left ventricular end-diastolic volume (LVEDV) index (mL/m2) and LVEF, with LVEDV index being a significant independent predictor of cfPWV (R2 = 0.42, p = 0.003). Central PP was significantly associated with heart rate, LVEF and LVEDV index, with the latter being a significant independent predictor of central PP (R2 = 0.41, p < 0.001). These correlations were not observed in healthy controls.
Conclusions: Significant associations between central hemodynamic measures and LV echocardiographic parameters were identified, suggesting the potential to use PWA and cfPWV as possible tools for managing HFrEF.
{"title":"Implications of pulse wave velocity and central pulse pressure in heart failure with reduced ejection fraction.","authors":"Anette Caroline Kõre, Tuuli Joonsalu, Martin Serg, Priit Pauklin, Jüri Voitk, Indrek Roose, Jaan Eha, Priit Kampus","doi":"10.1080/08037051.2024.2359932","DOIUrl":"https://doi.org/10.1080/08037051.2024.2359932","url":null,"abstract":"<p><strong>Background: </strong>Carotid-femoral pulse wave velocity (cfPWV) and central pulse pressure (PP) are recognised as significant indicators of vascular health and predictors of cardiovascular outcomes. In this study, associations between central hemodynamics and left ventricular (LV) echocardiographic parameters were investigated in subjects with heart failure with reduced ejection fraction (HFrEF), comparing the results to healthy individuals.</p><p><strong>Methods and results: </strong>This cross-sectional prospective controlled study included 50 subjects with HFrEF [mean LV ejection fraction (EF) 26 ± 6.5%] and 30 healthy controls (mean LVEF 65.9 ± 5.3%). Pulse wave analysis (PWA) and carotid-femoral pulse wave velocity (cfPWV) were used to measure central hemodynamics and arterial stiffness. The HFrEF group displayed higher cfPWV (8.2 vs. 7.2 m/s, <i>p</i> = 0.007) and lower central (111.3 vs. 121.7 mmHg, <i>p</i> = 0.001) and peripheral (120.1 vs. 131.5 mmHg, <i>p</i> = 0.002) systolic blood pressure. Central pulse pressure (PP) was comparable between the two groups (37.6 vs. 40.4 mmHg, <i>p</i> = 0.169). In the HFrEF group, cfPWV significantly correlated with left ventricular end-diastolic volume (LVEDV) index (mL/m<sup>2</sup>) and LVEF, with LVEDV index being a significant independent predictor of cfPWV (R<sup>2</sup> = 0.42, <i>p</i> = 0.003). Central PP was significantly associated with heart rate, LVEF and LVEDV index, with the latter being a significant independent predictor of central PP (R<sup>2</sup> = 0.41, <i>p</i> < 0.001). These correlations were not observed in healthy controls.</p><p><strong>Conclusions: </strong>Significant associations between central hemodynamic measures and LV echocardiographic parameters were identified, suggesting the potential to use PWA and cfPWV as possible tools for managing HFrEF.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2359932"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-01DOI: 10.1080/08037051.2024.2421214
E Lurbe, G Mancia, D Drozdz, S Erdine, F Fernandez-Aranda, M Litwin, M D Sinha, G Simonetti, S Stabouli, E Wühl
Purpose: Despite dramatic medical advances over the last few decades, cardiovascular disease remains a leading cause of death globally. High BP is clearly established, but modifiable, risk factor for early disability and death. Although most of the adverse outcomes occur in adulthood it has become clear that high BP is a life course problem that can become evident in early life however, relatively little attention has been paid to the problem of high BP in children and adolescents. Materials and methods: Being aware of the problem and the needs, the Task Force of the ESH Guidelines in children and adolescents took the initiative to move forward in the field, identifying the COST Action program. A proposal, HyperChildNET, was submitted, approved and funded for 4 years starting in October 2020. Results: The aim of the Action has been to establish a European sustainable and multidisciplinary network of researchers, clinicians, early career investigators, health economists, decision-makers, regulatory bodies, and medical devices manufacturers under the umbrella of the European Commission in order to acquire a holistic understanding of those factors affecting high BP in children and adolescents in order to propose and implement preventive and corrective actions. All the activities carried out during the 4 years are described. Conclusions: HyperChildNET offers a European perspective of the issue giving us the opportunity to develop new strategies and objectives moving forward in the field.
{"title":"HyperChildNET COST Action CA19115: report of the task force.","authors":"E Lurbe, G Mancia, D Drozdz, S Erdine, F Fernandez-Aranda, M Litwin, M D Sinha, G Simonetti, S Stabouli, E Wühl","doi":"10.1080/08037051.2024.2421214","DOIUrl":"https://doi.org/10.1080/08037051.2024.2421214","url":null,"abstract":"<p><p><b>Purpose:</b> Despite dramatic medical advances over the last few decades, cardiovascular disease remains a leading cause of death globally. High BP is clearly established, but modifiable, risk factor for early disability and death. Although most of the adverse outcomes occur in adulthood it has become clear that high BP is a life course problem that can become evident in early life however, relatively little attention has been paid to the problem of high BP in children and adolescents. <b>Materials and methods:</b> Being aware of the problem and the needs, the Task Force of the ESH Guidelines in children and adolescents took the initiative to move forward in the field, identifying the COST Action program. A proposal, HyperChildNET, was submitted, approved and funded for 4 years starting in October 2020. <b>Results:</b> The aim of the Action has been to establish a European sustainable and multidisciplinary network of researchers, clinicians, early career investigators, health economists, decision-makers, regulatory bodies, and medical devices manufacturers under the umbrella of the European Commission in order to acquire a holistic understanding of those factors affecting high BP in children and adolescents in order to propose and implement preventive and corrective actions. All the activities carried out during the 4 years are described. <b>Conclusions:</b> HyperChildNET offers a European perspective of the issue giving us the opportunity to develop new strategies and objectives moving forward in the field.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2421214"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-08-19DOI: 10.1080/08037051.2024.2390774
Pantelis Sarafidis, Kostas Tsioufis, Michel Burnier, Bryan Williams, Giuseppe Mancia, Thomas Weber, George S Stergiou
George L. Bakris passed away on 15 June 2024 at the age of 72 years. This obituary aims at honouring his life and career by describing the stages in his personal and professional pathway, presenting some of his many remarkable accomplishments, and highlighting his exceptional clinical skills, mentorship, and friendship.
{"title":"In remembrance: the life and legacy of George L. Bakris (1952-2024).","authors":"Pantelis Sarafidis, Kostas Tsioufis, Michel Burnier, Bryan Williams, Giuseppe Mancia, Thomas Weber, George S Stergiou","doi":"10.1080/08037051.2024.2390774","DOIUrl":"https://doi.org/10.1080/08037051.2024.2390774","url":null,"abstract":"<p><p>George L. Bakris passed away on 15 June 2024 at the age of 72 years. This obituary aims at honouring his life and career by describing the stages in his personal and professional pathway, presenting some of his many remarkable accomplishments, and highlighting his exceptional clinical skills, mentorship, and friendship.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2390774"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}